{"id":"NCT01475838","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","officialTitle":"A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2013-11","completion":"2014-12","firstPosted":"2011-11-21","resultsPosted":"2015-01-26","lastUpdate":"2016-06-08"},"enrollment":438,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"interventions":[{"type":"DRUG","name":"PI","otherNames":[]},{"type":"DRUG","name":"RTV","otherNames":[]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada"]},{"type":"DRUG","name":"Stribild","otherNames":[]}],"arms":[{"label":"Stribild","type":"EXPERIMENTAL"},{"label":"PI+RTV+FTC/TDF","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the non-inferiority of Stribild® (elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative to regimens consisting of a protease inhibitor (PI) boosted with ritonavir (RTV) plus Truvada® (FTC/TDF) fixed-dose combination in maintaining HIV-1 RNA \\< 50 copies/mL at Week 48 in virologically suppressed, HIV-1 infected adults. This study will also evaluate the safety, tolerability, and efficacy of the two regimens through 96 weeks of treatment.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"Stribild","deltaMin":93.8,"sd":null},{"arm":"PI+RTV+FTC/TDF","deltaMin":87.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":15},"locations":{"siteCount":99,"countries":["United States","Austria","Belgium","Canada","France","Germany","Italy","Portugal","Puerto Rico","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["24908551","24908550","28555519","26286337"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":293},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Headache","Back pain"]}}